Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/15/2011

a of PL-3994 and a new peptide drug candidate for sexual dysfunction.

CASH POSITIONPalatin's cash and cash equivalents were $14.9 million as of September 30, 2011, compared to $18.9 million at June 30, 2011, with current liabilities of $1.7 million as of September 30, 2011 compared to $2.8 million as of June 30, 2011.

Palatin believes, based on its current operating plan, that its cash and cash equivalents will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on November 15, 2011 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments.  Individuals interested in listening to the conference call live can dial 1-888-256-1007 (domestic) or 1-913-312-1466 (international), pass code 3249586. The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 3249586.  The webcast and telephone replay will be available through November 22, 2011.

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.  

Forward-looking Statements Statements
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... in part) in, into or from any jurisdiction where to ... of such jurisdiction.  Shire plc ("Shire" or the ... Bloomberg article this afternoon.  Shire confirms it has held a ... being made by Shire without the prior agreement or approval ...
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... July 10, 2014 Understanding the need ... cell lines, and the gap that currently exists in ... expand its industry-leading portfolio of validated ion channel and ... channel-expressing cell lines, as ion channels control many critical ... this activity creates the potential to treat a variety ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... With all the domestic and global issues going on ... the world's leaders viewed issues in yesterday's critical moments. ... had to shoulder huge responsibilities. They are worth applying ... perspectives may help broaden your view of things. That's ...
... startup and spin-off companies are gaining attention from ... of this is Primorigen Biosciences LLC , ... analysis of cellular reprogramming and differentiation. , ,Primorigen, ... related products, will use a pair of investments ...
... Wis. - Norlight Telecommunications, Inc., which ... announced that it will roll out its new Voice ... businesses in Green Bay and Madison. , ,The ... growth market by offering integrated communications bundles of local ...
Cached Biology Technology:Business leaders can learn from historical insights 2Business leaders can learn from historical insights 3Business leaders can learn from historical insights 4Business leaders can learn from historical insights 5Wisconsin start up Primorigen Biosciences corrals out-of-state investment 2Norlight will offer VoIP in Madison, Green Bay 2
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
(Date:7/10/2014)... COLORADO SPRINGS, Colo. , June 27, 2014 ... announces that the National Institute of Standards and ... appointed 10 of its academic research and forensic ... Board (FSSB).  The Board is an element of ... These AAFS members are among the first appointments ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... state of chronic inflammation. If chronic, the inflammation will ... devastating disease multiple sclerosis, hyperactivity of immune cells called ... Researchers at BRIC, the University of Copenhagen, have identified ... combat such hyperactive T-cells in blood from patients with ...
... Lincoln, Neb., Feb. 17, 2014 -- Fertilizer could be too much ... findings to be published online Feb. 16 by the journal ... nitrogen will increase the amount of grass that can be grown. ... are better adapted to survive in harsher times. It results in ...
... why skeletal muscle stem cells stop dividing and renewing ... opportunity for managing muscle-wasting conditions in humans, says a ... to CU-Boulder Professor Bradley Olwin, the loss of skeletal ... to sarcopenia, a debilitating muscle-wasting condition that generally hits ...
Cached Biology News:New blood cells fight brain inflammation 2Worldwide study finds that fertilizer destabilizes grasslands 2CU-Boulder stem cell research may point to new ways of mitigating muscle loss 2CU-Boulder stem cell research may point to new ways of mitigating muscle loss 3
... protein assay reagents package is used for determining ... and detergents. The RC DC protein assay is ... for 500 standard assays: 250 ml RC reagent ... alkaline copper tartrate solution, 2 L dilute Folin ...
... SureLINK Bioconjugation Kit provides a powerful ... carbohydrates and nuceleic acids. The kit provides ... with reagents for quantifying conjugation efficiencies. It ... fluorophores, biotin and other tags with a ...
...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Biology Products: